A detailed history of Lindbrook Capital, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 163 shares of AGIO stock, worth $5,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163
Previous 163 -0.0%
Holding current value
$5,610
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$41.19 - $49.72 $576 - $696
-14 Reduced 7.91%
163 $7,000
Q2 2024

Jul 31, 2024

BUY
$27.55 - $48.83 $826 - $1,464
30 Added 20.41%
177 $7,000
Q4 2023

Jan 31, 2024

SELL
$19.97 - $24.53 $199 - $245
-10 Reduced 6.37%
147 $3,000
Q3 2023

Oct 25, 2023

SELL
$24.36 - $28.18 $1,802 - $2,085
-74 Reduced 32.03%
157 $3,000
Q2 2023

Jul 28, 2023

BUY
$21.38 - $29.19 $2,907 - $3,969
136 Added 143.16%
231 $6,000
Q1 2023

Apr 26, 2023

SELL
$21.74 - $30.93 $1,173 - $1,670
-54 Reduced 36.24%
95 $2,000
Q4 2022

Jan 24, 2023

BUY
$24.81 - $31.52 $917 - $1,166
37 Added 33.04%
149 $0
Q3 2022

Nov 10, 2022

BUY
$19.51 - $34.14 $741 - $1,297
38 Added 51.35%
112 $3,000
Q2 2022

Aug 01, 2022

BUY
$17.06 - $31.42 $1,074 - $1,979
63 Added 572.73%
74 $2,000
Q1 2022

Apr 21, 2022

SELL
$26.68 - $34.81 $2,267 - $2,958
-85 Reduced 88.54%
11 $0
Q4 2021

Jan 18, 2022

SELL
$29.58 - $49.78 $1,153 - $1,941
-39 Reduced 28.89%
96 $3,000
Q4 2020

Jan 27, 2021

SELL
$33.21 - $46.54 $1,726 - $2,420
-52 Reduced 27.81%
135 $6,000
Q2 2020

Jul 27, 2020

BUY
$34.45 - $53.48 $1,791 - $2,780
52 Added 38.52%
187 $10,000
Q4 2019

Jan 27, 2020

BUY
$30.08 - $50.59 $4,060 - $6,829
135 New
135 $6,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.89B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.